Cytomegalovirus (HHV-5) Infections is an indication for drug development with over 100 pipeline drugs currently active. According to GlobalData, preregistered drugs for Cytomegalovirus (HHV-5) Infections have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Cytomegalovirus (HHV-5) Infections compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cytomegalovirus (HHV-5) Infections overview
Cytomegalovirus (CMV) is virus in the herpes family, also called HHV-5. CMV is spread through saliva or urine. Symptoms include fever, pneumonia, weight loss, and hearing, neurological, and developmental problems. The predisposing factors are direct contact with an infected surface or individual, weakened immune system, and congenital factors. It may be diagnosed by blood or urine tests. The condition may be controlled by the use of medication such as anti-virals and can be prevented by lifestyle modification.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Cytomegalovirus (HHV-5) Infections, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.